Daimler Truck Holding Azioni (OTC: DTRUY)

Ultime notizie per Daimler Truck Holding (OTC:DTRUY) Azioni

Daimler Truck Holding AG is a commercial vehicle manufacturer. It operates through various brands including Bharat Benz, Freightliner, Fuso, Mercedes-Benz, Setra, Thomas Built Buses, and Western Star. Its products include Trucks, Buses, and Financial Services. The Group has five reportable segments: Trucks North America, Mercedes-Benz Trucks, Trucks Asia, Daimler Buses, and Financial Services. It generates maximum revenue from the Trucks North America segment. The Trucks North America segment develops, manufactures and sells trucks under the Freightliner and Western Star brands in North America. The segment's product range also includes buses of Thomas Built Buses as well as bus chassis.

DAIMLER TRUCK HLDG S/ADR by DAIMLER TRUCK HLDG AG

Daimler Truck Holding AG

In the preceding three months, 19 analysts have released ratings for Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Estee Lauder Cos and provided 12-month price targets. The average target is $77.74, accompanied by a high estimate of $100.00 and a low estimate of $61.00. Experiencing a 0.8% decline, the current average is now lower than the previous average price target of $78.37. 
<img src="https://www.benzinga.com/files/images/story/2025/1744401624_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Estee Lauder Cos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $61.00&#x7C;$72.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $67.00&#x7C;$77.00 &#x7C; 
&#x7C;Linda Bolton Weiser &#x7C;DA Davidson &#x7C;Maintains &#x7C;Buy &#x7C; $81.00&#x7C;$81.00 &#x7C; 
&#x7C;Dara Mohsenian &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $81.00&#x7C;$85.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $64.00&#x7C;$71.00 &#x7C; 
&#x7C;Linda Bolton Weiser &#x7C;DA Davidson &#x7C;Maintains &#x7C;Buy &#x7C; $81.00&#x7C;$81.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $77.00&#x7C;$81.00 &#x7C; 
&#x7C;Susan Anderson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $70.00&#x7C;$76.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $76.00&#x7C;$76.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $76.00&#x7C;$76.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Christopher Carey &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $80.00&#x7C;$74.00 &#x7C; 
&#x7C;Korinne Wolfmeyer &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $98.00&#x7C;$91.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $76.00&#x7C;$76.00 &#x7C; 
&#x7C;Linda Bolton Weiser &#x7C;DA Davidson &#x7C;Maintains &#x7C;Buy &#x7C; $81.00&#x7C;$81.00 &#x7C; 
&#x7C;Steve Powers &#x7C;Deutsche Bank &#x7C;Lowers &#x7C;Hold &#x7C; $78.00&#x7C;$80.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $71.00&#x7C;$63.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $80.00&#x7C;$74.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $79.00&#x7C;$74.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Estee Lauder Cos. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Estee Lauder Cos compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Estee Lauder Cos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Estee Lauder Cos's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Estee Lauder Cos analyst ratings.</a>
<h2>Unveiling the Story Behind Estee Lauder Cos</h2>
Estee Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estee Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estee Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
<h3>Breaking Down Estee Lauder Cos's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Estee Lauder Cos's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -6.43%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -14.74%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Estee Lauder Cos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.75%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Estee Lauder Cos's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.87%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Estee Lauder Cos's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.25, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

19 Analysts Assess Estee Lauder Cos: What You Need To Know

AECOM's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) short percent of float has fallen 12.04% since its last report. The company recently reported that it has 2.43 million shares sold short, which is 2.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AECOM Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744401621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AECOM has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AECOM's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AECOM's peer group average for short interest as a percentage of float is 5.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on AECOM?

In the current market session, Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) price is at $102.35, after a 0.09% spike. However, over the past month, the stock decreased by 6.85%, and in the past year, by 17.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744401619_0.png" alt="Past Year Chart" />

<h3>A Look at Zimmer Biomet Holdings P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Zimmer Biomet Holdings has a lower P/E than the aggregate P/E of 79.42 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744401619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: Zimmer Biomet Holdings

WIIM

GOOG

GOOGL

Alphabet shares are trading higher amid overall market strength.

HUBB

SPLP

Shares of industrial and transportation stocks are trading higher as investors assess recent tariff developments.

Barclays analyst Saket Kalia maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and lowers the price target from $365 to $325.

Price Target

ADSK

Barclays Maintains Overweight on Autodesk, Lowers Price Target to $325

Barclays analyst Richard Hightower maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Equal-Weight and raises the price target from $226 to $227.

Barclays Maintains Equal-Weight on AvalonBay Communities, Raises Price Target to $227

APLD,BITF,CAN,CLSK,COIN,CORZ,HIVE,HUT,IREN,MARA,MSTR,RIOT,WULF

APLD

BITF

CLSK

COIN

Core Scientific, Inc. - Class A Common Stock

CORZ

HIVE

IREN

MARA

MSTR

RIOT

WULF

Shares of Bitcoin miners and crypto-linked stocks are trading higher amid strength in Bitcoin.

Barclays analyst Richard Hightower maintains Mid-America Apartment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) with a Equal-Weight and lowers the price target from $163 to $160.

Barclays Maintains Equal-Weight on Mid-America Apartment, Lowers Price Target to $160

Barclays analyst Richard Hightower maintains Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) with a Equal-Weight and raises the price target from $20 to $21.

Barclays Maintains Equal-Weight on Independence Realty Trust, Raises Price Target to $21

Barclays analyst Richard Hightower maintains Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) with a Equal-Weight and lowers the price target from $304 to $303.

Barclays Maintains Equal-Weight on Essex Property Trust, Lowers Price Target to $303

Barclays analyst Richard Hightower maintains Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) with a Overweight and lowers the price target from $130 to $127.

Barclays Maintains Overweight on Camden Prop Trust, Lowers Price Target to $127

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Gains Amid Ongoing Trade Volatility, Mar. Inflation Comes In Below Expectations, 10-Year Treasury Yield Rises

"I do not know of anybody who has done [market timing] successfully. I don't know anybody who knows anybody who has done it successfully and consistently" Jack Bogle, Founder Vanguard.
If you have read any of our blogs over the last several years, you would know that my firm, <a href="http://lcmcapital.com">LCM Capital Management</a>, despises my industry when it comes to predicting markets direction, economic activity or inflation and GDP growth or lack thereof.&nbsp; We always tell our clients to turn off the financial news networks and the talking heads since all they are doing is guessing and they typically guess wrong. We can't think of a better example than our present day.
Most everyone who invests has heard the following cliché', It's time in the market not timing the market. Our question is, do investors actually adhere to it? What about their brokers, advisors or CFP's?
We ask this simple question because based on what has happened to the stock market over the last month or even the last few weeks, aka since President Trump's tariffs announcement, it appears very few investors, besides my firm, seems to actually believe in this cliché'. Stocks had an unprecedented tumble. The S&amp;P 500 closed out the month of February at 5954. April 7th, it closed at 5062. That's approximately a 15% drop in a little over a month. Clearly people were selling. I intentionally used the word "people" since investors they are not.&nbsp;&nbsp;
Fast forward two days (an eternity, right?) April 9th and the S&amp;P 500 just had its single biggest day since 2008 jumping over 9.50%, in a single day! The cause? President Trump put a 90 day pause on many of his tariffs.
So now that this happened what should an investor do? If you sold on your own or were told to get out by your broker the question becomes, should or when do you get back in? The problem with trying to time the market is sure you may have gotten lucky and sold but now you have to get lucky again and know when to buy. One thing is for certain, most investors that were out probably missed this move today. And there was no reason to from our perspective. I say this with much certainty because according to an article on cnbc.com written by John Melloy and Hakyung Kim, Trump's pause declaration went out at 1:18 p.m. ET when the Dow was about 350 points higher for the day. Seconds later, the 30-stock index surged more than 2,000 points.  Read that again, seconds later the market moved over 5%. Now how many people got a call from their broker telling them to buy? It reminds me of when my kids were young and they would tell people that what their dad did for a living was make people "broker."
Watching your portfolio drop by 5 or 10 or 15% is not fun. I have yet to find anyone in my 37 years of managing money who likes losing money. But I am telling you that if you lived by the mantra of staying invested and not listening to the "experts" you'd be better off. Our clients certainly are.
These "experts" over the last few weeks and days have been warning investors of an impending recession or stagflation or something even worse. JP Morgan raised the odds of one to 60% on April 4th. Goldman Sachs raised the odds twice in a week and as of April 7th had a 45% probability of one, then today April 9th, according to the same website above, the following headline came out, Goldman forecast a recession then almost immediately rescinded it after Trump tariff pause. If this doesn't tell you everything you need to know about forecasting than nothing will. We mention this because whether or not a recession does actually materialize is just a guess and you should never invest on a guess. Remember when the Fed started its unprecedented rate hiking campaign back in 2021 and the yield curve went inverted, meaning short-term rates were higher than longer-term rates? Wall Street came out of the woodwork saying this always (90%+ of the time) leads to a recession. Well one never materialized. We can go on with plenty of examples of Wall St. and their awful predictions and we are sure not making one today but this market's volatility is not over and April 9th may or may not have been the bottom of this correction but what investors need to remember is the markets will always go up and down, sometimes violently, but if you stay invested to your risk tolerance and stay diversified throughout both stocks and bonds you can withstand any bout of market volatility and simply laugh the next time an "expert" tells you what will happen next.

Long Ideas

Opinion

ETFs

Time 'In' the Market: Do Investors Actually Adhere?

Barclays analyst Alex Scott maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Underweight and raises the price target from $52 to $62.

Barclays Maintains Underweight on WR Berkley, Raises Price Target to $62

Barclays analyst Alex Scott maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Underweight and raises the price target from $302 to $316.

Barclays Maintains Underweight on Willis Towers Watson, Raises Price Target to $316

Another busy stretch reminded the cannabis industry that momentum rarely moves in a straight line. 
Minnesota punted its adult‑use launch to at least 2026, while Germany's new coalition left legalization intact. In Latin America, Chile pushed a sweeping adult‑use bill even as Panama tightened medical rules and Italy stunned hemp operators with a sudden ban. 
Companies stayed active: SNDL Inc. (NASDAQ: SNDL) inked a 32‑store acquisition and started trading in Canada, MariMed Inc. (OTC: MRMD) elevated a longtime brand builder to chief commercial officer and Tilray Brands Inc. (NASDAQ: TLRY) trimmed guidance after softer cannabis sales. 
Below is a recap of every headline that mattered.
<h2 class="wp-block-heading">Politics And Regulation</h2>
<h3 class="wp-block-heading">U.S. Rescheduling Could Drift Under Trump</h3>
Former DEA adviser Matt Lawrence told an Ohio State University forum that, without explicit White House backing, the DEA might "do essentially nothing at all," leaving the Schedule III proposal in limbo. Former HHS counsel Patricia Zettler added that new DEA nominee Terrance Cole's long agency tenure "doesn't bode particularly well for support of rescheduling," warning that the simplest outcome may be prolonged delay.
The discussion, reported by <a class="" href="https://www.marijuanamoment.net/former-dea-and-hhs-officials-suggest-marijuana-rescheduling-could-be-delayed-indefinitely-if-trump-doesnt-proactively-support-it/">Marijuana Moment</a>, highlighted how politics—not science—will likely dictate the timetable. Speakers also noted that DEA could revive the process quickly if President Trump deems it a priority, but the administration's first‑year drug plan omitted any reference to cannabis reform.
<h3 class="wp-block-heading">Medicare And Medicaid Draw A Hard Line</h3>
The Centers for Medicare &amp; Medicaid Services finalized a rule clarifying that "alcohol, tobacco, and cannabis products" are ineligible as supplemental benefits in Medicare Advantage plans. CMS said it had fielded questions about covering medical marijuana but reiterated that cannabis remains illegal federally.
In the same notice—slated for the Federal Register on June 3—CMS specified that CBD products also fail the "primarily health related" test, effectively barring coverage. The policy details appear in the agency's rulemaking summary, also covered by <a class="" href="https://www.marijuanamoment.net/medicare-and-medicaid-officials-finalize-rule-to-clarify-that-medical-marijuana-isnt-covered-by-federal-health-programs/">Marijuana Moment</a>.
<h3 class="wp-block-heading">Minnesota's Retail Clock Slips</h3>
Consultant Stefan Egan, who helped draft Minnesota's adult‑use law, told <a class="" href="https://kstp.com/kstp-news/top-news/minnesota-marijuana-dispensaries-might-not-open-until-late-spring-2026/">KSTP‑TV</a> that absent final rules, licenses won't be issued before late spring 2026. Sen. Mark Koran projected another nine to twelve months for build‑outs and product testing, pushing first sales into late spring or early summer 2026.
Both sources warned that uncertainty hampers investment. The Office of Cannabis Management noted more than 1,000 qualified applicants stand ready once regulations land, but it offered no firm timeline.
<h3 class="wp-block-heading">Germany Keeps CanG in Place</h3>
Germany's new CDU/CSU‑SPD coalition will not roll back the 2024 legalization law. Instead, the government plans a "neutral evaluation" in autumn 2025.
The compromise came after Bavaria's CSU pushed for reinstating prohibition. Federal drug commissioner Burkhard Blienert called the existing framework "an important contribution to a more honest and decriminalized approach to drugs," urging patience until the review.
Read the full story on <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44716802/cannabis-stays-legal-in-germany-following-new-coalition-deal">Benzinga</a>
<h3 class="wp-block-heading">Chile Advances Adult‑Use Bill</h3>
A cross‑party coalition introduced legislation allowing six‑plant home‑grows, 40‑gram public possession and nonprofit cultivation clubs. Lead sponsor Ana María Gazmuri said the proposal "allows us to catch up with international standards."
Civil‑society leaders told El Planteo the bill addresses organized crime by offering legal access. Presidential contender Vlado Mirosevic pledged to champion legalization if elected, calling prohibition a "failure of drug policy."
Read the full story on <a href="https://www.benzinga.com/news/legal/25/04/44743798/chile-moves-to-legalize-adult-use-cannabis-with-backing-from-presidential-candidate">Benzinga</a>
<h3 class="wp-block-heading">Panama Regulates, Italy Prohibits</h3>
Panama's Decree No. 6 broadens physician prescribing rights but bans vaporizers, a restriction reformer Carlos Ossa called illogical because "70% of patients use vaporizers." Production licenses remain pending, so the country still relies on imports.
Only a few days before that, Italy issued an emergency decree banning all hemp and CBD flowers. Trade group Canapa Sativa Italia warned the move threatens up to 30,000 jobs and violates EU precedent that CBD is not a narcotic.
Read the full story on <a href="https://www.benzinga.com/markets/cannabis/25/04/44747982/one-step-forward-one-step-back-panama-regulates-cannabis-italy-bans-it">Benzinga</a>.
<h3 class="wp-block-heading">Netherlands Launches Supply‑Chain Pilot</h3>
Ten municipalities—including Arnhem, Groningen and Tilburg—began requiring coffeeshops to stock only state‑licensed cannabis. Hashish will follow once supply stabilizes, officials told Dutch media. Shop owner Willem Vugs welcomed the phased roll‑out, saying growers need time to "produce the right quality and variety."
The four‑year experiment, detailed by Dutch News reporting, aims to replace the decades‑old "back‑door" model where sales are tolerated but large‑scale cultivation remains illegal.
<h2 class="wp-block-heading">Corporate And Market Moves</h2>
<h3 class="wp-block-heading">SNDL Expands Retail Footprint And Lists On The CSE</h3>
SNDL Inc. agreed to buy 32 Cost Cannabis and T Cannabis stores from 1CM Inc. (CSE: EPIC) for C$32.2 million in cash, per the companies' joint release. CEO Zach George said the deal "aligns with our stated capital priorities" and boosts the network to 219 owned or franchised outlets.
The transaction—covering locations in Ontario, Alberta and Saskatchewan—generated C$53 million in revenue for 1CM's fiscal 2024. Closing is expected by Q3 2025, pending court and shareholder approval, after which 1CM plans to return "a substantial portion" of the proceeds to investors.
Two days after the acquisition announcement, SNDL began trading on the Canadian Securities Exchange under the same ticker. George said the move "creates optionality for shareholders" and positions the company to pursue growth with "greater agility."
The CSE listing allows investors to trade shares in Canadian dollars and fits the exchange's cannabis‑friendly framework, according to SNDL's statement.
<h3 class="wp-block-heading">MariMed Names Chief Commercial Officer</h3>
MariMed Inc. promoted Ryan Crandall—co‑creator of Betty's Eddies Chews—to chief commercial officer. CEO Jon Levine credited Crandall with building "our innovative and trusted portfolio of brands."
Crandall, who joined MariMed in 2018, will oversee sales, marketing, product development and retail. He called the role "a fantastic journey" and pledged to strengthen MariMed's market position.
<h3 class="wp-block-heading">Scotts Miracle‑Gro Spins Off Hawthorne Collective</h3>
The Scotts Miracle‑Gro Company (NYSE: SMG) transferred its Hawthorne Collective investment arm to an independent partner in exchange for an interest‑bearing note. CEO Jim Hagedorn said the move reduces cannabis‑sector volatility and lets Scotts focus on core lawn and garden products.
The company retains an option to reacquire Hawthorne Collective if federal reform—such as rescheduling or the SAFER Banking Act—boosts sector prospects. Hagedorn noted that "four years of unkept promises" have hampered growth.
<h3 class="wp-block-heading">Tilray Trims Revenue Outlook</h3>
Tilray Brands reported Q3 revenue of $185.8 million, down from $188.3 million a year earlier and below consensus. Cannabis sales fell to $54.3 million, while beverage alcohol rose slightly to $55.9 million.
Citing SKU rationalization and a shift of product from Canada to higher‑margin export markets, Tilray cut its FY‑2025 revenue target to $850–900 million from up to $1 billion, as detailed in <a class="" href="https://www.benzinga.com/25/04/44685827/tilray-brands-reports-lower-cannabis-sales-in-q3-trims-2025-revenue-outlook">Benzinga</a>.
<h2 class="wp-block-heading">Market Forecasts</h2>
<h3 class="wp-block-heading">Whitney Economics Slashes U.S. Sales Projections</h3>
Data firm Whitney Economics reduced its 2025–2030 U.S. retail forecast by $21.1 billion, blaming oversupply, high taxes and hemp‑derived substitutes. Founder Beau Whitney said, "Lower prices, lower participation and more substitutes will result in lower revenues."
California took the biggest hit, with a $606 million downgrade for 2025. New York and Maryland were bright spots, reflecting faster‑growing new markets. 
Read the full story on <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44720279/is-legal-weed-in-trouble-analyst-says-taxes-oversupply-and-hemp-threat-drove-a-21b-cut-in-sales-estimates">Benzinga</a>.
<h2 class="wp-block-heading">Science, Education &amp; Events</h2>
<h3 class="wp-block-heading">Avicanna Calls Clinicians To Toronto</h3>
Avicanna Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTC">AVCNF</a>) (TSX: AVCN) will host its fifth medical symposium—"From Emerging Evidence to Clinical Practice"—on June 6 at Toronto's MaRS Discovery District. Executive VP Dr. Karolina Urban said the gathering aims to "enhance our collective understanding of cannabinoid‑based medicines."
Speakers include researchers from Washington State, Johns Hopkins and the University of British Columbia, covering topics from CBG's therapeutic potential to opioid–cannabinoid interactions. Healthcare professionals can register or submit poster abstracts at <a class="" href="https://www.avicanna.com/symposium">avicanna.com/symposium</a>.
<h3 class="wp-block-heading">Argentina Explores Cannabis Tourism And Chemo Pain Relief</h3>
Mendoza passed a law creating a provincial cannabis registry, while entrepreneur Gonzalo Llamas Bianchetti's Proyecto Vallecitos seeks to revive an abandoned ski town with hemp‑based eco‑lodging and cultivation. Provincial health leader Daniel Llaver said the registry focuses on patient access and industry compliance.
Separately, a three‑year preclinical study by CONICET and Universidad Austral found a 1:1 CBD‑THC oral blend prevented chemotherapy‑induced neuropathic pain in rats without added toxicity. Both stories were detailed in <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44745709/from-malbec-to-marijuana-argentinas-provincial-push-fuels-cannabis-tourism-science-and-policy">Benzinga</a>.
<h2 class="wp-block-heading">Recommended Reads Of The Week</h2>
<ul>
<li><a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44720917/whos-blocking-cannabis-reform-in-the-senate-marijuana-policy-remains-a-dividing-line-between-democrats-and-republicans">Who's Blocking Cannabis Reform in the Senate?</a></li>
<li><a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44752007/latino-entrepreneurs-are-thriving-in-nycs-cannabis-market-heres-the-proof">Latino Entrepreneurs Are Thriving in NYC's Cannabis Market—Here's the Proof</a></li>
<li><a class="" href="https://www.forbes.com/sites/javierhasse/2025/04/08/ice-t-says-he-doesnt-get-high-so-why-did-he-open-a-cannabis-dispensary-with-a-playboy-playmate/">Ice‑T Says He Doesn't Get High—So Why Did He Open a Cannabis Dispensary With a Playboy Playmate?</a></li>
</ul>
Check back next week for a new recap of what&#8217;s going on in the most exciting industry in the world. Until then, stay high(drated).

Cannabis

Politics

AVCNF

MRMD

SNDL

TLRY

The Week In Cannabis: Delays, Decrees And Deals Reshape The Global Playbook

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator's choice of lenvatinib or sorafenib1
In the trial, 38% of patients were still alive at 3 years with this dual immunotherapy vs. 24% with the comparator arm1
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54232125&amp;newsitemid=20250401202312&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=20eae49edc15fde8c3534a6ef92b3f6d">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo&#xAE;(nivolumab) plus Yervoy&#xAE; (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common primary liver cancer.1,2 This approval is based on the results from the global Phase 3 randomized, open-label CheckMate-9DW trial evaluating the combination of Opdivo plus Yervoy compared to investigator's choice of tyrosine kinase inhibitor monotherapy (lenvatinib or sorafenib) in patients with unresectable or metastatic HCC who have not received prior systemic therapy.1 In the trial, Opdivo plus Yervoy demonstrated statistically significant overall survival (OS) and overall response rate (ORR) vs the comparator arm.1 It is the only trial supporting an FDA approval to show superior results against this comparator arm.

FDA Approves Bristol Myers Squibb's Opdivo plus Yervoy as First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Barclays analyst Alex Scott maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Equal-Weight and lowers the price target from $75 to $66.

VOYA

Barclays Maintains Equal-Weight on Voya Financial, Lowers Price Target to $66

Barclays analyst Alex Scott maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Overweight and raises the price target from $85 to $89.

Comments

Daimler Truck Holding

Notizie

Ultime notizie per Daimler Truck Holding (OTC:DTRUY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO